Nuvalent insider trades under 10b5-1 plan; option exercises and sale
Rhea-AI Filing Summary
Nuvalent insider activity: option exercises and a planned sale under a 10b5-1 plan. Henry E. Pelish, Nuvalent's Chief Scientific Officer, acquired shares through option exercises and sold shares pursuant to a pre-established trading plan. On 08/07/2025 Pelish exercised options to acquire 731 shares at $18.93, 877 shares at $27.85 and 3,892 shares at $29.33, and sold 5,500 shares at $74.85. After these transactions his reported direct beneficial ownership is 60,956 shares. The filing notes the trades were effected under a Rule 10b5-1 plan adopted November 1, 2024, and includes vesting schedules for the options.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider option exercises and a scheduled sale under a 10b5-1 plan; not an unexpected governance event.
The filing documents option exercises (731, 877 and 3,892 shares at exercise prices of $18.93, $27.85 and $29.33) and a sale of 5,500 shares at $74.85 under a Rule 10b5-1 plan. This pattern—exercise then sale under a pre-established plan—is common for executives converting equity compensation to cash while maintaining ongoing ownership. The reported direct beneficial ownership after the transactions is 60,956 shares, which provides a snapshot of current insider holdings but does not, by itself, indicate a change in strategic control or company fundamentals.
TL;DR: Governance controls appear in place: transactions executed under a documented 10b5-1 plan with disclosed vesting terms.
The report explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted November 1, 2024, which supports an affirmative defense to timing allegations. The filing also discloses vesting schedules for the exercised options, enhancing transparency about when shares became or will become exercisable. From a governance perspective, the disclosure meets standard insider reporting expectations and shows adherence to planned execution rather than opportunistic timing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 731 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 877 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 3,892 | $0.00 | -- |
| Exercise | Class A Common Stock | 731 | $18.93 | $14K |
| Exercise | Class A Common Stock | 877 | $27.85 | $24K |
| Exercise | Class A Common Stock | 3,892 | $29.33 | $114K |
| Sale | Class A Common Stock | 5,500 | $74.85 | $412K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2024. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following March 1, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
